Pharmaceutical

Amneal’s CREXONT gains FDA approval for Parkinson’s treatment

The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals' CREXONT extended-release capsules for PD.

Aug 9, 2024 - 04:00
Amneal’s CREXONT gains FDA approval for Parkinson’s treatment
The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals' CREXONT extended-release capsules for PD.
Read the original article

Tags:

Previous Article

Takeda’s ADZYNMA gains EU approval for cTTP treatment

Next Article

GSK’s Jemperli approved for advanced endometrial cancer in Singapore

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Generate Biomedicines partners with MD Anderson to develop cancer therapies

Generate Biomedicines partners with MD Anderson to deve...

Apr 28, 2023

STAT+: Sarepta’s Duchenne gene therapy fails to meet primary endpoint in pivotal trial

STAT+: Sarepta’s Duchenne gene therapy fails to meet pr...

Oct 30, 2023

Studies highlight risks of excluding people with obesity from drug trials

Studies highlight risks of excluding people with obesit...

Oct 16, 2023